Thomas Eddy, DPM
Podiatrist · Murray, UTNPI 1528354693
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,739 of the $6,677 with a category attached, or 71.0%. 43 manufacturers reported payments, led by Integra Lifesciences Corporation at 25.8% of the total. Reporting peaked in 2022 at $2,539 and has fallen 95.3% since, to $121 in 2025.
Across 207 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$2K
- Anika Therapeutics, Inc.$931
- Amgen$685
- Abbott$394
- Zyla Life Sciences, Inc.$392
- Boston Scientific$277
- plus $2K from 37 others
What the payments were for
- Travel & lodging$1,93129%
- Food & beverage$4,73971%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$2,521
- INTEGRA DERMAL REGENERATION TEMPLATE$840
- PRIMATRIX$840
- TACTOSET$539
- ACell$417
- NEURAGEN$417
- HemiCAP$367
- KRYSTEXXA$241
- SUPERA$158
- HOFFMANN$132
- Perclose ProGlide suture mediated closure system$122
- Stravix$122
- Grafix$122
- STRAVIX PL$122
- GRAFIX PL$122
- Qutenza$120
- Supera peripheral stent system$114
- GENERAL VASCULAR INTERVENTION$114
- Zynrelef$110
How this compares
$6,677 in reported general payments places this provider in the 85th percentile of 59 podiatrist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 19 | $301 |
| Terbinafine Hcl | 13 | $61 |
| Meloxicam | 12 | $43 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Murray
- Clark LarsenMurray$16K
- Clint LarsenMurray$984
- Louis LarsenMurray$45
- Jason BruseLayton$203K
- Anna HronekSalt Lake City$82K
- Michele CarrDraper$56K
- David GraffOgden$39K
- Kelly HamblinWest Jordan$13K
- Mikol AndersonSalt Lake City$9K
- Andrew EvansSt George$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.